Invention Grant
- Patent Title: Steroidal esters of 17-oximino-5-androsten-3beta-ol
- Patent Title (中): 17-肟基-5-雄甾-3β-醇的甾体酯
-
Application No.: US12733415Application Date: 2008-08-14
-
Publication No.: US08435975B2Publication Date: 2013-05-07
- Inventor: Tilak Raj Bhardwaj , Manoj Kumar , Neelima Dhingra , Neraj Mehta
- Applicant: Tilak Raj Bhardwaj , Manoj Kumar , Neelima Dhingra , Neraj Mehta
- Applicant Address: IN New Delhi
- Assignee: Council of Scientific & Industrial Research
- Current Assignee: Council of Scientific & Industrial Research
- Current Assignee Address: IN New Delhi
- Agency: Abelman, Frayne & Schwab
- Priority: IN1805/DEL/2007 20070824
- International Application: PCT/IN2008/000513 WO 20080814
- International Announcement: WO2009/027994 WO 20090305
- Main IPC: A61K31/568
- IPC: A61K31/568 ; C07J41/00 ; A61P5/28

Abstract:
The present invention relates to steroidal esters of 17-oximino-5-androsten-3-ol, of compound of general formula (A) wherein R is selected from a group consisting of arylalkyl, aryl, substituted aryl. The ester derivatives are synthesized starting from Dehydroandrosterone acetate. The compounds were tested for their antiproliferative activity and 5α-reductase inhibitory activity in comparison to Finasteride. Decreased androgen level have been found in serum of animal treated with newly synthesized compounds. These compounds have also shown better cytotoxicity in comparison to reference drug Finasteride. Thus such compounds can be useful in treatment of androgen dependent disorder of prostate alone or by synergistic effect they can decrease the size of prostate due to their antiproliferative activity.
Public/Granted literature
- US20100292201A1 NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3BETA-OL Public/Granted day:2010-11-18
Information query